Pyrotinib Plus Trastuzumab and Chemotherapy for HER2-Positive Early Breast Cancer

Clinical trial NCT07635342 · RECRUITING

Trial details

NCT number: NCT07635342
Sponsor: Hebei Medical University Fourth Hospital
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

HER2-positive Breast Cancer

Start date: 2024-04-30
Primary completion: 2026-12-31
Enrollment: 182

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.